Rhenman & Partners Asset Management Ab Bridge Bio Pharma, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.2 Billion
- Q3 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 268,000 shares of BBIO stock, worth $7.65 Million. This represents 0.57% of its overall portfolio holdings.
Number of Shares
268,000
Previous 184,500
45.26%
Holding current value
$7.65 Million
Previous $4.67 Million
46.01%
% of portfolio
0.57%
Previous 0.46%
Shares
4 transactions
Others Institutions Holding BBIO
# of Institutions
290Shares Held
170MCall Options Held
10.4MPut Options Held
2.37M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY25.3MShares$721 Million35.94% of portfolio
-
Viking Global Investors LP25.1MShares$717 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$405 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$355 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$173 Million63.58% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $4.23B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...